Sermorelin
The original FDA-approved GHRH analog that stimulates the pituitary to release growth hormone in a natural, pulsatile pattern.
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH 1-29) — the shortest sequence that fully activates the GHRH receptor. By binding GHRH receptors on pituitary somatotrophs it stimulates endogenous, pulsatile GH secretion while preserving the natural hypothalamic-pituitary feedback axis, meaning it cannot overshoot into supraphysiologic GH levels the way recombinant HGH can. Originally FDA-approved as Geref for pediatric growth hormone deficiency and withdrawn from the US market in 2008 for commercial rather than safety reasons, it is now used off-label in adult anti-aging and hormone-optimization practice via compounding pharmacies.
Class
Synthetic GHRH analog (GHRH 1-29 peptide)
Half-life
~10–20 minutes (subcutaneous); approximately 6 minutes by IV
Routes
Subcutaneous injection
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Natural pulsatile GH stimulation
Sermorelin triggers endogenous growth hormone release in a physiologic pulsatile pattern by agonizing pituitary GHRH receptors, restoring a secretion rhythm that resembles the nocturnal GH burst of a healthy young adult. Because somatostatin tone still gates the response, it preserves the natural feedback axis rather than bypassing it like recombinant HGH.
Improved sleep quality and slow-wave sleep
Nightly dosing improves slow-wave (deep) sleep architecture — the phase responsible for the majority of daily GH secretion. Community reports and clinical observation note better sleep quality within a few weeks of consistent use, often the earliest noticeable effect.
Body composition improvement
Sustained nightly administration produces modest gains in lean body mass (roughly 1.2–2.8 kg over 16 weeks in older adults in trial data) alongside reductions in visceral and subcutaneous fat, mediated by a gradual rise in IGF-1 into the upper quartile of the age-adjusted normal range.
IGF-1 elevation within physiologic range
Consistent dosing raises IGF-1 by roughly +50 to +120 ng/mL from baseline, plateauing at a new setpoint rather than accumulating because of the short half-life. Effects are best understood as physiologic restoration toward a younger secretion pattern, not supraphysiologic elevation.
Enhanced recovery
Adults commonly report improved recovery between workouts over months of use, consistent with GH/IGF-1 axis support of tissue repair. Effects are modest and slow rather than dramatic.
Anti-aging and skin quality
Restoring a more youthful GH secretion pattern is associated with improved skin thickness and elasticity, effects that typically take 12–16 weeks of consistent dosing to become measurable.
Mechanism
How it works
Sermorelin is a truncated analog comprising the first 29 amino acids of the 44-amino-acid native GHRH molecule produced by the arcuate nucleus of the hypothalamus. The 1-29 fragment retains full biological activity because the C-terminal residues 30-44 contribute to peptide stability but not to receptor binding or activation. It is the parent compound from which more stable analogs — mod GRF 1-29, tesamorelin, and the CJC-1295 family — were later derived through stability-enhancing modifications.
When sermorelin binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed almost exclusively on anterior pituitary somatotrophs, it activates Gs-protein signaling, elevating cyclic AMP and protein kinase A. This drives transcriptional upregulation of the GH1 gene and exocytosis of preformed GH granules, producing a strong pulsatile release of growth hormone. When co-administered with a ghrelin-mimetic GHRP, it also potentiates the ghrelin/GHS-R1a pathway for synergistic release.
The defining feature of GHRH-driven GH release is that it remains subject to somatostatin tone — the body's endogenous GH inhibitor acts as a ceiling on how much GH any given GHRH pulse can elicit. Consequently sermorelin cannot produce supraphysiologic GH levels the way HGH injections can, and it preserves the natural ultradian rhythm of GH secretion. Dose-response data show that increasing a single injection beyond roughly 500 mcg yields diminishing returns because the somatostatin ceiling prevents further release.
Sermorelin's short serum half-life of about 10–20 minutes is both its main limitation and its most elegant feature: rapid clearance prevents receptor desensitization, allows downstream somatostatin pulses to suppress GH between cycles, and mimics the brief GHRH pulses that occur naturally every 2–3 hours. This is why IGF-1 elevations plateau rather than accumulate, but it also mandates daily dosing since the peptide is degraded by DPP-4.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Sermorelin ships as a lyophilized powder, typically in 2 mg or 5 mg vials. Reconstitute with bacteriostatic water to a concentration of 1 mg/mL (e.g., add 2 mL of BAC water to a 2 mg vial). Swab both stoppers, run the water down the side of the glass rather than directly onto the powder, and gently swirl — do not shake — until the solution is clear and colorless. At 1 mg/mL, 200 mcg = 0.2 mL = 20 units, 300 mcg = 30 units, and 500 mcg = 50 units on a U-100 insulin syringe.
Beginner
- Dose
- 200–300 mcg
- Frequency
- 7 nights/week
- Timing
- Once nightly at bedtime, within 1 hour of sleep onset, in a fasted state (3+ hours after last meal)
- Duration
- 12–16 weeks minimum to assess response
- Route
- Subcutaneous
Rotate injection sites between abdomen, thigh, and flank. Baseline labs (IGF-1, fasting insulin, HbA1c, metabolic panel) before starting; recheck IGF-1 at weeks 6 and 12.
Intermediate
- Dose
- 300–500 mcg
- Frequency
- 5–7 nights/week
- Timing
- Bedtime, fasted
- Duration
- Months 4–12 of continuous use
- Route
- Subcutaneous
Optional 5 days on / 2 days off cycling to guard against receptor adaptation. Some practitioners transition to a GHRH + GHS combination here (sermorelin 200–300 mcg + ipamorelin 200–300 mcg). Monitor IGF-1 every 3 months, fasting glucose every 6 months.
Advanced
- Dose
- 400–500 mcg (often stacked)
- Frequency
- 5–7 nights/week
- Timing
- Bedtime, fasted, same injection as stacked GHS
- Duration
- 16 weeks on / 4 weeks off with cycling
- Route
- Subcutaneous
Performance/recomposition stack: sermorelin 400–500 mcg + ipamorelin 200–300 mcg nightly, optionally BPC-157 250–500 mcg BID for connective-tissue support. Quarterly IGF-1 and comprehensive metabolic monitoring.
Historical pediatric (Geref)
- Dose
- 30 mcg/kg/day
- Frequency
- Daily
- Timing
- Per original label
- Duration
- Per treatment protocol
- Route
- Subcutaneous
The FDA-approved pediatric GH deficiency dose; provided for historical/regulatory context only. Adult use is off-label and not derived from these figures.
- Inject at bedtime to synchronize with the natural nocturnal GH pulse, which peaks roughly 60–90 minutes after sleep onset; daytime dosing is less effective because somatostatin tone is higher during waking hours.
- Dose in a fasted state — at least 3 hours after the last meal — because elevated insulin and blood glucose blunt GH release through somatostatin potentiation.
- Avoid alcohol within 2 hours of dosing, as alcohol suppresses GH secretion, and keep timing consistent since the GH axis entrains to a regular schedule.
- The single-dose ceiling is around 500 mcg; higher amounts are simply capped by somatostatin and wasted.
- Target IGF-1 in the upper quartile of the age-adjusted reference range, not the upper limit or supraphysiologic values; reduce dose or take a washout if IGF-1 exceeds the reference range.
- Store lyophilized vials refrigerated at 2–8°C (stable up to 2 years sealed); use reconstituted solution within 30 days, never freeze, and protect from light.
- Do not dose during active febrile infection, in severe caloric deficit (anabolic signal is blunted), or if fasting glucose is consistently above 110 mg/dL until the metabolic state is addressed.
Evidence
Research & clinical studies (3)
The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency
In a randomized controlled dose-response study, sermorelin produced a dose-dependent GH secretory response in healthy controls that was markedly attenuated in adults with post-irradiation GH insufficiency, confirming pituitary somatotroph responsiveness as the mechanism behind sermorelin-based GH stimulation.
PMID 10754477The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin in growth hormone pulse generation
In a randomized peptide clamp study, continuous GHRH(1-29) infusion amplified GH secretory peak concentrations and, combined with intermittent somatostatin withdrawal, reliably generated pulsatile GH release, clarifying the mechanistic basis for GHRH analog-based GH augmentation.
PMID 10594518Sermorelin: A Review of its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency
A comprehensive review of sermorelin's clinical use, summarizing its efficacy in diagnosing and treating pediatric idiopathic growth hormone deficiency and its favorable safety profile.
Combinations
Stacking & blends
Sermorelin + Ipamorelin
Amplified, physiologic GH release for body composition and recovery
The classic GHRH + GHS pairing. Sermorelin acts on GHRH receptors while ipamorelin acts on ghrelin (GHS-R1a) receptors on the same somatotrophs, producing roughly 3–5x amplification of GH pulse amplitude versus either alone. Ipamorelin's selectivity — no cortisol, prolactin, or ACTH elevation — makes it the cleanest ghrelin mimetic to combine with sermorelin. Typical stack: 200–300 mcg of each in the same bedtime injection.
Sermorelin + GHRP-2
Muscle growth, fat loss, and GH support for age-related decline
A synergistic combination of a GHRH analog and a ghrelin-mimetic GHRP that activates two distinct receptor pathways to amplify natural growth hormone release, commonly researched for body composition and recovery.
Recomposition & Recovery Stack
Body recomposition with connective-tissue support during training
Adds BPC-157 (250–500 mcg BID) to the sermorelin + ipamorelin base for connective-tissue repair during periods of training intensification; an advanced-tier protocol requiring monitoring.
Sermorelin + Testosterone
Additive anabolic support in men with clinically low testosterone
A well-established synergy where the anabolic effects of GH-axis stimulation and testosterone replacement are additive.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active malignancy — particularly hormone-responsive cancers (breast, prostate, endometrial) given theoretical IGF-1-driven tumor concern
- Pregnancy and lactation (no established safety data)
- Known hypersensitivity to sermorelin, GHRH analogs, or any excipient
- Strong family history of GH-axis responsive cancers (specialist supervision only)
- Severe untreated sleep apnea (stabilize with CPAP/APAP first)
- Acute critical illness (sepsis, major trauma, post-surgical, respiratory failure)
- Diabetic ketoacidosis or severe uncontrolled diabetes
- Untreated pituitary tumor or hypothyroidism (treat first)
- Active proliferative retinopathy (relative)
Side effects in the original pediatric Geref trials were mild — injection-site reactions, occasional flushing, and transient headache. Because it is a pure GHRH analog rather than a ghrelin-receptor secretagogue, cortisol and prolactin effects are minimal. Discontinue if persistent joint pain, peripheral edema, carpal tunnel symptoms, or elevated fasting glucose develop, as these suggest IGF-1 has risen beyond the optimization range. Long-term safety in adults at optimization dosing is less characterized than the pediatric approval data, and sustained IGF-1 elevation carries a theoretical (unproven) cancer concern.
FAQ
Sermorelin — common questions
What is sermorelin and how does it work?
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the active N-terminal fragment of GHRH — the hypothalamic hormone that signals the pituitary to release growth hormone. It binds GHRH receptors on pituitary somatotrophs, triggering pulsatile endogenous GH release that respects the body's natural negative feedback. Unlike recombinant HGH, it cannot produce supraphysiologic GH because somatostatin limits how much GH any single pulse can elicit.
Is sermorelin still FDA-approved?
Sermorelin was FDA-approved as Geref (diagnostic 1990, pediatric growth hormone deficiency 1997) and voluntarily discontinued from the US market in 2008 for commercial reasons, not safety or efficacy — a determination the FDA confirmed in 2013. There is no current FDA-approved sermorelin product; the peptide remains legally available through 503A/503B compounding pharmacies when prescribed off-label for adults.
What is the best sermorelin dosage?
The typical adult protocol is 200–500 mcg subcutaneously once nightly at bedtime. Beginners start at 200–300 mcg to assess tolerance and titrate to 300–500 mcg after 6–12 weeks based on IGF-1 response. The single-dose ceiling is around 500 mcg — beyond that, somatostatin tone prevents further GH release. Always dose fasted (3+ hours after the last meal) to avoid an insulin-driven somatostatin surge that would blunt GH release.
How long does sermorelin take to work?
Peak serum GH occurs within 15–30 minutes of a single injection, but clinically meaningful effects take weeks of consistent nightly dosing. Sleep improvements often appear within 2–3 weeks, IGF-1 stabilizes at a new setpoint around weeks 4–6, lean body mass changes are detectable by weeks 8–12, and skin changes take 12–16 weeks.
Can I stack sermorelin with ipamorelin?
Yes — sermorelin + ipamorelin is the classic and most well-established GHRH + GHS combination. The two bind different receptors on the same somatotrophs and produce roughly 3–5x amplification of GH pulse amplitude versus either alone. Ipamorelin's selectivity (no cortisol, prolactin, or ACTH elevation) makes it the cleanest partner. Typical stack is 200–300 mcg of each in the same bedtime injection.
How is sermorelin different from CJC-1295?
Sermorelin is pure GHRH(1-29) with a 10–20 minute half-life. CJC-1295 without DAC (mod GRF 1-29) adds stability substitutions for a ~30-minute half-life; CJC-1295 with DAC adds an albumin-binding tether extending half-life to 6–8 days. Sermorelin and no-DAC CJC-1295 give pulsatile release; DAC produces continuous stimulation that raises baseline GH/IGF-1 more but eliminates pulsatility. Sermorelin is the most conservative, physiologic choice.
Does sermorelin cause weight loss?
It is not primarily a weight-loss compound. It produces modest reductions in visceral and subcutaneous fat over 12–16 weeks alongside lean-mass gains of similar magnitude, improving the fat-to-lean ratio rather than driving dramatic weight loss. For aggressive fat loss, GLP-1 agonists or tesamorelin (for visceral fat specifically) are more potent.
Does sermorelin show up on a drug test?
Sermorelin and other GHRH analogs are on the WADA Prohibited List (Section S2 — Peptide Hormones), and competitive athletes face sanctions for use. Detection methods for GHRH analogs in anti-doping testing have improved.
